文献速递免疫规划

古巴七价肺炎球菌结合疫苗在健康婴儿中的安全性与免疫原性:一项双盲随机对照Ⅰ期试验结果

Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I.
PubMed 文献 · Vaccine · 2018-07-10

古巴研发的新型七价肺炎球菌结合疫苗(PCV7-TT)在30名未接种健康婴儿中开展Ⅰ期双盲随机对照试验,20名接种PCV7-TT、10名接种Synflorix®,采用2p+1程序于7、8、11月龄接种。PCV7-TT安全性与Synflorix®相似,局部反应为主、全身事件轻微,加强后对1、14、18C、19F型100%婴儿IgG抗体浓度≥0.35µg/ml。

要点

  • PCV7-TT安全性与Synflorix®相似,局部反应为主、全身事件轻微。
  • 加强后1、14、18C、19F型100%婴儿IgG≥0.35µg/ml。
  • PCV7-TT组基础免疫后OPA应答比例≥89.5%,加强后达100%。

核心结论

  • 古巴PCV7-TT在健康婴儿中安全、耐受良好且具有免疫原性。

研究设计与样本

  • Ⅰ期对照、随机、双盲临床试验,纳入30名未接种健康婴儿,20名分配至PCV7-TT组、10名分配至Synflorix®对照组,于7、8月龄(基础系列)和11月龄(加强剂)接种。
  • 于第二剂后30天和加强后采集血样,用ELISA和OPA检测抗体,统计分析包括不良事件发生频率和免疫应答,免疫应答比较采用非参数检验。
  • 临床试验已在古巴公共临床试验注册中心注册,注册号RPCEC00000173。

主要发现

  • PCV7-TT总体安全性与Synflorix®相似,局部反应为主,全身事件严重程度轻微。
  • 肿胀和发红常与PCV7-TT相关,主要在第一剂后(分别为50%和40%)。
  • 15%受试者在PCV7-TT第一剂后报告严重肿胀,10%受试者在Synflorix®第二剂后报告严重肿胀。
  • 报告的全身事件为轻度发热(≥38-≤39)、呕吐和睡眠障碍。
  • 加强后每组对1、14、18C和19F型达到肺炎球菌IgG抗体浓度≥0.35µg/ml的婴儿均为100%;对5、6B和23F型,Synflorix®或PCV7-TT接种婴儿中超过80%达到保护性IgG GMC≥0.35µg/ml。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cuba has a new pneumococcal conjugate vaccine candidate (PCV7-TT). This study evaluates the safety and immunogenicity in healthy infants using 2p+1 vaccination schedule. METHODS: A phase I, controlled, randomized and double blind clinical trial was designed. 30 unvaccinated healthy infants were included. 20 subjects were assigned to study group (PCV7-TT) and 10 to control group (Synflorix®) to receive the vaccines at 7, 8 months of age (primary series) and 11 months (booster dose). Blood samples were collected 30 days after second dose and post booster for antibodies measure analysis by ELISA and OPA. The statistics analysis included the frequency of occurrence for adverse events and the immune response. Non-parametric tests were used to compare the immune response. The clinical trial was published in the Cuban Public Register of Clinical Trials with code RPCEC00000173 available at http://registroclinico.sld.cu. RESULTS: Overall, the safety profile of PCV7-TT was similar to Synflorix®. Local reactions were predominant and systemic events were mild in severity. Swelling and redness were frequently associated with PCV7-TT mainly after the first dose (50% and 40% respectively). 15% and 10% of subject reported severe swelling after first dose with PCV7-TT and after second dose with Synflorix®. Mild fever (≥38-≤39), vomiting and sleep disturb were the systemic events reported. 100% of infants achieved pneumococcal IgG antibody concentrations ≥0.35 µg/ml after booster dose for serotypes 1, 14, 18C and 19F in each vaccine group. For serotypes 5, 6B and 23F, more than 80% infants vaccinated with Synflorix® or PCV7-TT achieved protective IgG GMC ≥ 0.35 µg/ml after booster dose. OPA proportion's responders to the seven common serotypes were 89.5% or more after the primary dose and 100% after booster dose in vaccinated with PCV7-TT. CONCLUSIONS: The Cuban PCV7-TT is safe, well tolerated and immunogenic in healthy infants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martínez CPD, Linares-Pérez N, Toledo-Romaní ME, et al. Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I. Vaccine. 2018. PMID: 30005948. doi:10.1016/j.vaccine.2018.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。